Patents Examined by Lei Yao
  • Patent number: 10293035
    Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: May 21, 2019
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Mary L. Disis, Denise Cecil, Meredith Slota
  • Patent number: 10294288
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 21, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10280468
    Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 7, 2019
    Assignee: Almac Diagnostics Limited
    Inventors: Denis Paul Harkin, Richard Kennedy, Katherine E. Keating, Andrena McCavigan, Laura A. Hill, Steve Deharo, Timothy Davison, Fionnuala Patterson, Sinead Donegan, Gera Jellema, Charlie Gourley
  • Patent number: 10273308
    Abstract: The disclosure provides methods of making antibodies specific for p95.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: April 30, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Jeff Sperinde, John William Winslow, Xueguang Jin, Gerald J. Wallweber
  • Patent number: 10273282
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: April 30, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10259875
    Abstract: Materials and methods for treating cancer especially in patients identified as having elevated levels of Bim are disclosed. Specifically, the disclosure provides a method for treating a mammal having cancer, the method comprises: (a) identifying said mammal as containing an elevated level of Bim, and (b) administering to said mammal an anti-B7-H1 antibody, an anti-PD-1 antibody, an anti-CD80 antibody, or a fusion protein comprising a portion of PD1 or a portion of CD80, under conditions wherein the interaction of naturally occurring B7-H1 with PD-1 or CD80 in said mammal is reduced after said administering.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: April 16, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Haidong Dong, Susan M. Harrington, Eugene D. Kwon, Christopher J. Krco, Xin Liu
  • Patent number: 10259874
    Abstract: Anti-TIM-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer, infectious diseases, or T-cell dysfunctional disorders. Bispecific antibodies against TIM-3 and other targets are also disclosed, with preferred embodiment of a bispecific antibody against TIM-3 and CD3.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: April 16, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Hsueh Ling Janice Oh, Siok Ping Yeo, Yun Pei Sharon Goh
  • Patent number: 10253098
    Abstract: The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: April 9, 2019
    Assignee: GREENOVATION BIOTECH GMBH
    Inventors: Manfred Schuster, Ralf Kircheis, Andreas Nechansky, Wolfgang Jost, Gilbert Gorr
  • Patent number: 10253108
    Abstract: The present invention provides a mutated antibody of the fully humanized HER2 antibody GB235-019, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the mutated antibody are respectively SEQ ID NO: 10, SEQ ID NO: 2; SEQ ID NO: 11, SEQ ID NO: 2; or SEQ ID NO: 12, SEQ ID NO: 2. The mutated antibody has the ability to specifically bind to human HER2 antigen, similar to the GB235-019 antibody. They can also be used in combination with additional HER2 positive tumor therapeutic agents for treating HER2 positive tumor, weakly positive tumor or negative tumor.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: April 9, 2019
    Assignee: Genor Biopharma Co., Ltd.
    Inventors: Qing Zhou, Mengjun Shu, Zhuzi He, Jun Lin
  • Patent number: 10246517
    Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: April 2, 2019
    Assignee: APROGEN KIC INC.
    Inventors: Yoo Ri Moon, Gil Yong Ji
  • Patent number: 10239930
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10226519
    Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: March 12, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Gentao Liu, Keith L. Black
  • Patent number: 10226518
    Abstract: A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 12, 2019
    Assignees: UbiVac, LLC, Providence Health & Science—Oregon
    Inventors: Christopher Twitty, Erik LeShane, Bernard Fox, Hong-Ming Hu, Guangjie Yu
  • Patent number: 10221229
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: March 5, 2019
    Assignee: INMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10221460
    Abstract: Provided herein are methods for the prognosis of prostate cancer progression in a patient by analyzing the gene expression in a tumor sample obtained from the patient the prognosis of prostate cancer progression in a patient by analyzing the gene expression in a tumor sample obtained from the patient. In particular, gene expression levels of GCOM1, MEX3D, TRPM4, ATPAF1, PTRF, GLYATL1, FLNA, OBSCN, STRA13, WHSC1, ARFGAP3, KDM2A, FAM83H, CLDN7, CNOT6, and B3GNT9 are measured. Kits containing means for the measurement of gene expression as described herein and methods for treatment of prostate cancer are also provided.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: March 5, 2019
    Assignee: Washington State University
    Inventors: Grant D. Trobridge, Arun Kumar Nalla
  • Patent number: 10221240
    Abstract: The application provides methods of detection, diagnosis, prognosis, prophylaxis and treatment of folate receptor-alpha-expressing gastric cancer using antibodies that specifically bind to folate receptor alpha.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 5, 2019
    Assignee: Eisai, Inc.
    Inventor: Yasutsuna Sasaki
  • Patent number: 10222376
    Abstract: The present invention provides methods and compositions for identifying leukemic stem cells.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 5, 2019
    Assignee: The Charlotte-Mecklenburg Hospital Authority
    Inventor: Jonathan M. Gerber
  • Patent number: 10215761
    Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: February 26, 2019
    Assignee: Expression Pathology, Inc.
    Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Patent number: 10214577
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: February 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10202635
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Ephrin Type-A Receptor 2 (EPHA2) protein are provided that are particularly advantageous for quantifying the EPHA2 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 12, 2019
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough